Akeso Inc. Announces NMPA Acceptance of sNDA for Ivonescimab Combined with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Reuters
07-28
Akeso Inc. Announces NMPA Acceptance of sNDA for Ivonescimab Combined with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

Akeso Inc. has announced that the National Medical Products Administration (NMPA) has accepted its supplementary New Drug Application (sNDA) for ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. This marks the third accepted application for ivonescimab in China, building on previous submissions for its use in other forms of non-small cell lung cancer. The decision is based on positive outcomes from the Phase III HARMONi-6 study, which demonstrated the superiority of ivonescimab combined with chemotherapy over existing treatments. Ivonescimab is currently involved in several clinical trials worldwide, further establishing its role in global cancer immunotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN38376) on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10